(12) **Translation of European patent specification**

(11) **NO/EP 2699598 B1**

NORWAY

(19) NO

(51) Int Cl.

C07K 16/28 (2006.01)
A61K 39/395 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.06.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.03.06
(86)	European Application Nr.	12713849.3
(86)	European Filing Date	2012.04.09
(87)	The European Application's Publication Date	2014.02.26
(30)	Priority	2011.04.19, US, 201161477153 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
(72)	Inventor	ELLIOTT, Mark William, 10766 Sabre Hill Drive 257, San Diego, California 92128, USA FISHER, Timothy Scott, 7336 Via Cresta Road, San Diego, California 92129, USA SHARP, Leslie Lynne, 12417 Shropshire Lane, San Diego, California 92128, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INDUCING ANTIBODIES FOR THE TREATMENT OF CANCER**

(56) References Cited:

WO-A1-2012/032433
WO-A2-2005/000901
WO-A1-2006/088447
WO-A1-2011/071871
WO-A1-2005/035584
WILCOX RYAN A ET AL: "Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors", JOURNAL OF CLINICAL INVESTIGATION, vol. 109, no. 5, 1 March 2002 (2002-03-01) , pages 651-659, XP002396136, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US ISSN: 0021-9738, DOI: 10.1172/JCI200214184
HOLBROOK E. KOHRT ET AL: "Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer", JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 3, 1 March 2012 (2012-03-01) , pages 1066-1075,

XP055034582, ISSN: 0021-9738, DOI: 10.1172/JCI61226
R. HOUOT ET AL: "Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion", BLOOD, vol. 114, no. 16, 15 October 2009 (2009-10-15), pages 3431-3438, XP055034665, ISSN: 0006-4971, DOI: 10.1182/blood-2009-05-223958
Ajay K Gopal ET AL: "A phase I study of PF-05082566 (anti-1-1BB)+rituximab in patients with CD20+NHL", Journal of Clinical Oncology, Annual Meeting, 29 May 2015 (2015-05-29), XP055322904, Retrieved from the Internet: URL:http://meeting.ascopubs.org/cgi/content/abstract/33/15 [retrieved on 2016-11-24]
H. E. KOHRT ET AL: "CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies", BLOOD, vol. 117, no. 8, 24 February 2011 (2011-02-24), pages 2423-2432, XP055034541, ISSN: 0006-4971, DOI: 10.1182/blood-2010-08-301945
KOHRT HOLBROOK E ET AL: "Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy (abstract 422)", BLOOD , vol. 116, no. 21 1 November 2010 (2010-11-01), XP002681291, Retrieved from the Internet: URL:http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/422?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=immunomodulation&searchid=1&FIRSTINDEX=0&volume=116 &issue=21&resourcetype=HWCIT [retrieved on 2012-08-03]
H. NARAZAKI ET AL: "CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells", BLOOD, vol. 115, no. 10, 11 March 2010 (2010-03-11), pages 1941-1948, XP055034669, ISSN: 0006-4971, DOI: 10.1182/blood-2008-12-192591
ROCH HOUOT ET AL: "Immunomodulating antibodies and drugs for the treatment of hematological malignancies", CANCER AND METASTASIS REVIEWS, vol. 30, no. 1, 28 January 2011 (2011-01-28), pages 97-109, XP019885789, KLUWER ACADEMIC PUBLISHERS, DO ISSN: 1573-7233, DOI: 10.1007/S10555-011-9274-3

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Anti-4-1BB-antistoff eller antigenbindende del derav, for anvendelse i behandlingen av kreft i kombinasjon med et anti-CD20-antistoff eller en antigenbindende del derav, hvori anti-4-1BB-antistoffet eller den antigenbindende delen derav omfatter:
(a) et H-CDR1 som angitt i SEQ ID NO:29;
(b) et H-CDR2 som angitt i SEQ ID NO:30;
(c) et H-CDR3 som angitt i SEQ ID NO:31;
(d) et L-CDR1 som angitt i SEQ ID NO:34;
(e) et L-CDR2 som angitt i SEQ ID NO:35; og
(f) et L-CDR3 som angitt i SEQ ID NO:36;
og hvori anti-CD20-antistoffet eller den antigenbindende delen derav administreres ved en dosering fra 3–15 mg/kg.

2. Anti-4-1BB-antistoffet eller antigenbindende del derav, for anvendelse ifølge krav 1, hvori anti-CD20-antistoffet eller den antigenbindende delen derav omfatter de 6 CDR-ene til rituximab.

3. Anti-4-1BB-antistoffet eller antigenbindende del derav, for anvendelse ifølge krav 1 eller 2, hvori anti-4-1BB-antistoffet eller den antigenbindende delen derav omfatter en V_H-region omfattende aminosyresekvensen angitt i SEQ ID NO:43 og en V_L-region omfattende aminosyresekvensen angitt i SEQ ID NO:45.

4. Anti-4-1BB-antistoffet eller antigenbindende del derav, for anvendelse ifølge hvilket som helst av kravene 1 to 3, hvori anti-CD20-antistoffet eller den antigenbindende delen derav omfatter V_H-regionen til rituximab og V_L-regionen til rituximab.

5. Anti-4-1BB-antistoffet eller antigenbindende del derav, for anvendelse ifølge hvilket som helst av kravene 1 to 4, hvori anti-4-1BB-antistoffet eller den antigenbindende delen derav omfatter en tungkjede-aminosyresekvens som angitt i SEQ ID NO:44 og ytterligere omfatter en lettkjede-aminosyresekvens angitt i SEQ ID NO:46, under forutsetning at den C-terminale lysinresten til SEQ ID NO:44 eventuelt er fraværende.

6. Anti-4-1BB-antistoffet eller antigenbindende del derav, for anvendelse ifølge hvilket som helst av kravene 1 to 5, hvori anti-CD20-antistoffet eller den antigenbindende delen derav omfatter tungkjede-aminosyresekvensen til rituximab og lettkjede-aminosyresekvensen til rituximab.